Impact of BAALC expression on clinical outcome
. | Low BAALC n = 43 . | High BAALC n = 43 . | P . |
|---|---|---|---|
| Complete remission, n (%) | 35 (81) | 33 (77) | .79 |
| Relapse rate, n (%) | 10 (29) | 17 (52) | .08 |
| Death in CR, n (%) | 2 (6) | 3 (9) | .67 |
| Overall survival | |||
| Median, y | 5.8* | 1.7 | |
| Percent alive at 3 y (95% CI) | 60 (45-75) | 39 (24-54) | .02 |
| Event-free survival | |||
| Median, y | 4.9* | 0.8 | |
| Percent event-free at 3 y (95% CI) | 55 (40-70) | 30 (16-43) | .03 |
| Disease-free survival | |||
| Median, y | 7.3* | 1.4 | |
| Percent disease-free at 3 y (95% CI) | 68 (52-84) | 39 (22-56) | .03 |
. | Low BAALC n = 43 . | High BAALC n = 43 . | P . |
|---|---|---|---|
| Complete remission, n (%) | 35 (81) | 33 (77) | .79 |
| Relapse rate, n (%) | 10 (29) | 17 (52) | .08 |
| Death in CR, n (%) | 2 (6) | 3 (9) | .67 |
| Overall survival | |||
| Median, y | 5.8* | 1.7 | |
| Percent alive at 3 y (95% CI) | 60 (45-75) | 39 (24-54) | .02 |
| Event-free survival | |||
| Median, y | 4.9* | 0.8 | |
| Percent event-free at 3 y (95% CI) | 55 (40-70) | 30 (16-43) | .03 |
| Disease-free survival | |||
| Median, y | 7.3* | 1.4 | |
| Percent disease-free at 3 y (95% CI) | 68 (52-84) | 39 (22-56) | .03 |
CI indicates confidence interval.
Nonparametric estimate of the median is not available. Tabled value represents the median, assuming the survival estimate after the last observation follows an exponential curve. The median follow-up for patients alive was 3.3 years (range, 1.6-5.0 years, n = 40).